A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT03859427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.
Study identification
- NCT ID
- NCT03859427
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 454 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 8, 2019 (Actual)
- Primary completion
- Mar 31, 2023 (Actual)
- Completion
- Mar 31, 2023 (Actual)
- Last update posted
- Aug 13, 2024
2019 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Robert A Moss Oncology | Fountain Valley | California | 92708 | — |
| Rocky Mountain Cancer Centers Denver Midtown | Denver | Colorado | 80218 | — |
| Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut | Plainville | Connecticut | 06062 | — |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Advocate Lutheran General Hospital | Park Ridge | Illinois | 60068 | — |
| New York Oncology Hematology, PC | Albany | New York | 12208 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Texas Oncology-Denton | Denton | Texas | 76201 | — |
| US Oncology Research Investigational Products Center | Fort Worth | Texas | 76177 | — |
| Oncology Consultants PA | Houston | Texas | 77030 | — |
| Texas Oncology | San Antonio | Texas | 78229 | — |
| United States Oncology Regulatory Affairs Corporate Office | The Woodlands | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03859427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2024 · Synced Oct 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03859427 live on ClinicalTrials.gov.